Executive Team
Neal M. Farber, Ph.D.
Elkan Gamzu, Ph.D.
Daniel Katzman, M.Sc.
Esteban Fridman, M.D.
Eyal S. Ron, Ph.D.

Neal M. Farber, Ph.D., Chief Executive Officer
Dr. Farber has over 20 years experience in the biopharmaceutical industry in areas of research and product development. As President and CEO of Collgard Biopharmaceuticals, he raised $7 MM in a series A financing; completed a $40 MM corporate deal with a medical device company; initiated Phase I and II clinical trials in autoimmune and cancer programs; and signed development agreements with the NCI, EORTC, Mayo Clinic and the Walter Reed Army Hospital. Previously, Dr. Farber held senior corporate development positions at Biogen, Cubist Pharmaceuticals, and T Cell Sciences. Dr. Farber was a Helen Hay Whitney Research Fellow at Harvard University and received his PhD (Hammett Award) from Columbia University.

Return to top

Elkan Gamzu, Ph.D., Chairman of the Board, Acting Head of Clinical Trials
Dr. Gamzu has worked in the biopharmaceutical industry since 1971, in discovery with Hoffmann La Roche, in clinical management and drug development with Warner-Lambert, where as VP, Drug Development had responsibility for the development of Cognex, the first drug approved for Alzheimer's, and Neurontin. Dr. Gamzu served as CEO of Cambridge Neuroscience and as Interim VP of Development Project Leadership for Millennium Pharmaceuticals. He is a co-founder of BioPharmAnalysis, LLC, a company offering due diligence services and currently serves as Principal of enERGetics, LLC, a biopharmaceutical consulting company. Dr. Gamzu currently serves the boards of directors of Pharmos Corp. (NASDAQ: PARS) and Neurotech S.A.

Return to top

Daniel Katzman M.Sc., President and Founder
Mr. Katzman has over ten years of experience in the life sciences industry. Before founding NeuroHealing he served as VP of Business Development at Oridion Medical Ltd, a publicly traded company (Zurich SWX: ORIDN). By leading one of Oridion’s two divisions, Mr. Katzman supervised clinical trials, regulatory approval, intellectual property and marketing. Additionally, he has been granted four US patents, has led a pivotal, multi-center Phase III study and has obtained FDA approval for a drug-device combination product which included an NDA and a 510(k). Mr. Katzman received his graduate degree in Biochemistry from Universidad Nacional de La Plata, Argentina.

Return to top

Esteban Fridman, M.D., Chief Medical Advisor
Dr. Fridman is a Board Certified Neurologist in Argentina and former Fellow of the US National Institute of Neurological Diseases and Stroke (NINDS), part of the National Institutes of Health (NIH), Bethesda, MD. Dr. Fridman currently serves as an extra-mural investigator for the NINDS. Dr. Fridman also leads the Neurorehabilitation section at the FLENI Hospital, a leading Argentinean institution specializing in neurosciences. Dr. Fridman was awarded a three-year National Grant from the NIH in 2002.

Return to top

Eyal S. Ron, Ph.D., Senior Director of Formulation Development
Dr. Ron is an expert in the development of drugs, biomaterials and drug delivery systems. He has contributed to the formation of Cerebrotec, eNOS Pharmaceuticals, Focal, GelMed/Gel Sciences and InfiMed. Under his leadership numerous products have been developed and approved, including oral sustained release products (PefusiaTM); implantable, biodegradable, sustained release devices (Gliadel®, InFuse®, ProLease®); biodegradable sealants (FocalSeal®); and transmucosal delivery systems. Dr. Ron is the author of over 100 papers, book chapters and abstracts, and the inventor of over 30 patents mostly in the area of new indications for drugs, drug formulations, drug delivery, and biomaterials. Dr. Ron holds a PhD in chemistry from Brandeis and completed a post-doctoral fellowship at MIT under Robert Langer.

Return to top